Have a personal or library account? Click to login
Prescriptions for Alpha Agonists and Antipsychotics in Children and Youth with Tic Disorders: A Pharmacoepidemiologic Study Cover

Prescriptions for Alpha Agonists and Antipsychotics in Children and Youth with Tic Disorders: A Pharmacoepidemiologic Study

Tremor and Other Hyperkinetic Movements
Volume 9 (2019): Issue 0
By: Nicholas Cothros,  Davide Martino,  Carly McMorris,  David Stewart,  Ali Tehrani and  Tamara Pringsheim  
Open Access
|Jul 2019

References

  1. 1SangerTD, ChenD, FehlingsDL, HallettM, LangAE, MinkJW, et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord 2010;25(11):1538–1549. doi: 10.1002/mds.23088.20589866
    Back to article
  2. 2PatelN, JankovicJ, HallettM Sensory aspects of movement disorders. Lancet Neurol 2014;13(1):100–112. doi: 10.1016/S1474-4422(13)70213-8.24331796
    Back to article
  3. 3YangJ, HirschL, MartinoD, JetteN, RobertsJ, PringsheimT The prevalence of diagnosed tourette syndrome in Canada: a national population-based study. Mov Disord 2016;31(11):1658–1663. doi: 10.1002/mds.26766.27548401
    Back to article
  4. 4GanosC, MartinoD, PringsheimT Tics in the pediatric population: pragmatic management. Mov Disord Clin Pract 2017;4(2):160–172. doi: 10.1002/mdc3.12428.28451624
    Back to article
  5. 5HollisC, PennantM, CuencaJ, GlazebrookC, KendallT, WhittingtonC, et al. Clinical effectiveness and patient perspectives of different treatment strategies for tics in children and adolescents with Tourette syndrome: a systematic review and qualitative analysis. Health Technol Assess 2016;20(4):1–450. doi: 10.3310/hta20040.
    Back to article
  6. 6PárragaHC, HarrisKM, PárragaKL, BalenGM, CruzC An overview of the treatment of Tourette's disorder and tics. J Child Adolesc Psychopharmacol 2010;20(4):249–262. doi: 10.1089/cap.2010.0027.20807063
    Back to article
  7. 7MartinoD, PringsheimTM Tourette syndrome and other chronic tic disorders: an update on clinical management. Expert Rev Neurother 2018;18(2): 125–137. doi: 10.1080/14737175.2018.1413938.29219631
    Back to article
  8. 8PringsheimT, DojaA, GormanD, McKinlayD, DayL, BillinghurstL, et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. Can J Psychiatry 2012;57(3):133–143. doi: 10.1177/07067437120570030222397999
    Back to article
  9. 9RoessnerV, PlessenKJ, RothenbergerA, LudolphAG, RizzoR, SkovL, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry 2011;20(4):173–196. doi: 10.1007/s00787-011-0163-7.21445724
    Back to article
  10. 10FaragM, SternJS, SimmonsH, RobertsonMM Serial pharmacological prescribing practices for tic management in Tourette syndrome. Hum Psychopharmacol Clin Exp 2015;30(6):435–441. doi: 10.1002/hup.2495.
    Back to article
  11. 11GuyattGH, OxmanAD, VistGE, KunzR, Falck-YtterY, Alonso-CoelloP, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924–926. doi: 10.1136/bmj.39489.470347.AD.18436948
    Back to article
  12. 12PringsheimT, LamD, TanoDS, PattenSB The pharmacoepidemiology of antipsychotics for adults with schizophrenia in Canada, 2005 to 2009. Can J Psychiatry 2011;56(10):630–634. doi: 10.1177/07067437110560100922014696
    Back to article
  13. 13LamD, GormanDA, PattenS, PringsheimT The pharmacoepidemiology of selective serotonin reuptake inhibitors for children and adolescents in Canada from 2005 to 2009: a database analysis. Pediatr Drugs 2013;15(4): 319–327. doi: 10.1007/s40272-013-0014-8.
    Back to article
  14. 14ZitoJM, SaferDJ, JanhsenK, FegertJM, GardnerJF, GlaeskeG, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Mental Health 2008;2(1):26. doi: 10.1186/1753-2000-2-26.
    Back to article
  15. 15BachmannCJ, MantheyT, Kamp-BeckerI, GlaeskeG, HoffmannF Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany. Res Dev Disabil 2013;34(9):2551–2563. doi: 10.1016/j.ridd.2013.05.028.23747941
    Back to article
  16. 16BachmannCJ, LemppT, GlaeskeG, HoffmannF Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012. Dtsch Ärztebl Int 2014;111(3):25. doi: 10.3238/arztebl.2014.0025.24606780
    Back to article
  17. 17BachmannCJ, RoessnerV, GlaeskeG, HoffmannF Trends in psycho- pharmacologic treatment of tic disorders in children and adolescents in Germany. Eur Child Adolesc Psychiatry 2015;24(2):199–207. doi: 10.1007/s00787-014-0563-6.24888751
    Back to article
  18. 18RickardsH, CavannaAE, WorrallR Treatment practices in Tourette syndrome: the European perspective. Eur J Paediatr Neurol 2012;16(4):361–364. doi: 10.1016/j.ejpn.2011.12.001.22178398
    Back to article
  19. 19YooHK, JoungYS, LeeJS, SongDH, LeeYS, KimJW, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder. J Clin Psychiatry 2013;74(8):e772–e780. doi: 10.4088/JCP.12m08189.24021518
    Back to article
  20. 20SalleeF, KohegyiE, ZhaoJ, McQuadeR, CoxK, SanchezR, et al. Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette's disorder in children and adolescents. J Child Adolesc Psychopharmacol 2017;27(9):771–781. doi: 10.1089/cap.2016.0026.28686474
    Back to article
  21. 21BauchnerH, SimpsonL, ChessareJ Changing physician behaviour. Arch Dis Child 2001;84(6):459–462. doi: 10.1136/adc.84.6.45911369556
    Back to article
  22. 22PringsheimT, HoJ, SarnaJR, HammerT, PattenS Feasibility and relevance of antipsychotic safety monitoring in children with Tourette syndrome: a prospective longitudinal study. J Clin Psychopharmacol 2017;37(5):498–504. doi: 10.1097/JCP.0000000000000760.28816926
    Back to article
  23. 23KurlanR Treatment of ADHD in children with tics: a randomized con- trolled trial. Neurology 2002;58(4):527–536. doi: 10.1212/WNL.58.4.52711865128
    Back to article
  24. 24JooSW, KimH-W Treatment of children and adolescents with attention deficit hyperactivity disorder and/or Tourette's disorder with clonidine extended release. Psychiatry Investig 2018;15(1):90. doi: 10.4306/pi.2018.15.1.90.
    Back to article
  25. 25CavannaAE, SelviniC, TermineC, BalottinU, EddyCM Tolerability profile of clonidine in the treatment of adults with Tourette syndrome. Clin Neuropharmacol 2012;35(6):269–272. doi: 10.1097/WNF.0b013e3182741c39.23123691
    Back to article
  26. 26PiacentiniJ, WoodsDW, ScahillL, WilhelmS, PetersonAL, ChangS, et al. Behavior therapy for children with Tourette disorder: a randomized con- trolled trial. JAMA 2010;303(19):1929–1937. doi: 10.1001/jama.2010.607.20483969
    Back to article
  27. 27SteevesT, McKinlayBD, GormanD, BillinghurstL, DayL, CarrollA, et al. Canadian guidelines for the evidence-based treatment of tic disorders: behavioural therapy, deep brain stimulation, and transcranial magnetic stimula- tion. Can J Psychiatry 2012;57(3):144–151. doi: 10.1177/07067437120570030322398000
    Back to article
  28. 28TakahashiY, NishidaY, AsaiS Utilization of health care databases for pharmacoepidemiology. Eur J Clin Pharmacol 2012;68(2):123–129. doi: 10.1007/s00228-011-1088-2.21808989
    Back to article
  29. 29TanakaS, SetoK, KawakamiK Pharmacoepidemiology in Japan: medical databases and research achievements. J Pharm Health Care Sci 2015;1(1):16. doi: 10.1186/s40780-015-0016-5.26819727
    Back to article
  30. 30OyinlolaJO, CampbellJ, KousoulisAA Is real world evidence influencing practice? A systematic review of CPRD research in NICE guidances. BMC Health Serv Res 2016;16(1):299. doi: 10.1186/s12913-016-1562-8.27456701
    Back to article
  31. 31HallGC, SauerB, BourkeA, BrownJS, ReynoldsMW, CasaleRL Guidelines for good database selection and use in pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2012;21(1):1–10. doi: 10.1002/pds.2229.
    Back to article
  32. 32StoneTT, SchweikhartSB, ManteseA, SonnadSS Guideline attribute and implementation preferences among physicians in multiple health systems. Qual Manag Healthcare 2005;14(3):177–187. PMID: .16027596
    Back to article
DOI: https://doi.org/10.5334/tohm.459 | Journal eISSN: 2160-8288
Journal RSS Feed
Language: English
Submitted on: Jan 31, 2019
Accepted on: Jun 14, 2019
Published on: Jul 15, 2019
Published by: Columbia University Libraries/Information Services
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Tic disorders,
Tourette syndrome,
pharmacoepidemiology,
antipsychotics,
alpha agonists

© 2019 Nicholas Cothros, Davide Martino, Carly McMorris, David Stewart, Ali Tehrani, Tamara Pringsheim, published by Columbia University Libraries/Information Services
This work is licensed under the Creative Commons License.

Previous articleVolume 9 (2019): Issue 0Next article